Ko, Justin
Gauthier, Genevieve
Kurosky, Samantha K.
Takiya, Liza
Sadrarhami, Mojgan M.
Bell, Griffith
Lee, Yi-Chien
Ungar, Benjamin
Funding for this research was provided by:
Pfizer
Article History
Received: 10 March 2026
Accepted: 18 May 2026
First Online: 6 June 2026
Declarations
Conflict of Interest: Justin Ko has served as a consultant and/or investigator for Pfizer, Eli Lilly, Sanofi, and Abbvie. Genevieve Gauthier, Samantha K. Kurosky, Liza Takiya, Mojgan M. Sadrarhami, Griffith Bell, and Yi-Chien Lee are employees of and may hold stock or stock options in Pfizer. Benjamin Ungar is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, and Sanofi. He is also a consultant for AbbVie, Arcutis Biotherapeutics, Apogee Therapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Ebla Holdco, Fresenius Kabi, Galderma, J&J, Leo Pharma, Lilly, Nektar Therapeutics, Pfizer, Primus Pharmaceuticals, Sanofi, Sun Pharma, UCB, Veradermics, and VRG Therapeutics.
Ethical Approval: In accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulatory framework, Mirador Analytics Inc. has conducted a statistical disclosure risk analysis of Komodo’s Komodo + OMNY dataset. This constitutes an Expert Determination as set out in 45 CFR § 164.514(b)(1). The Expert Determination confirmed that the dataset met the HIPAA Expert Determination de-identification standard. Accordingly, approval from an institutional review board was not required, and informed consent was not obtained.